Souhaitez-vous accéder aux communiqués récents ?

Growing role of machine learning, deep learning and predictive analytics in addressing clinical, operational and economic challenges in kidney care.

Austin, TX, USA, June 17, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “GLP-1 Receptor Agonist Market Size, Trends and Insights By Product Type...

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

Eledon Announces Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes (T1D) at UChicago Medicine

Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use

•Translational data presented at ADA demonstrate icovamenib’s potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including...

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...

It was an honor to attend the keynote address of Dr. Izpisúa whose scientific interests and vision for the future of humanity are world renowned

Arlington, VA, June 01, 2026 (GLOBE NEWSWIRE) -- New online community brings together people navigating GLP-1 medications, diabetes, obesity, metabolic health, and related conditions to learn,...